*6.5.2 A case study: repurposing FDA-approved antiviral protease inhibitors as SARS-CoV-2 3CLpro inhibitors*

As mentioned in Section 3.2, due to the important role in the viral life cycle alongside the absence of closely related homologs in humans, the 3CLpro is considered a proper target for discovering effective antiviral drugs against *SARS-CoV-2*. Therefore, here a molecular docking-based drug-repurposing process was planned to screen the 3CLpro inhibitor(s) among the standard antiviral protease blockers.
